Dr. Hwang on the Addition of Radium-223 to Abiraterone Acetate and Prednisone in mCRPC

Video

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride (Xofigo) to abiraterone acetate (Zytiga) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases.

In the trial, investigators examined the addition of radium-223, a bone-targeting agent and alpha emitter, in this patient population, says Hwang. Investigators know that when radium-223 is used in bone-predominant disease, it can improve survival based on the data from the ALSYMPCA trial. The primary end point of the ERA-223 trial was symptomatic skeletal event-free survival. Data from the primary analysis revealed that 49% of patients in the radium-223 group experienced at least 1 symptomatic skeletal event or died, compared with 47% in the placebo group. The median symptomatic skeletal event-free survival was 22.3 months in the radium-223 group versus 26.0 months in the placebo group.

Unfortunately, the trial was negative and there was a signal that these skeletal events would be increased with the addition of radium-223, Hwang adds. This trial shows that there may be some bone toxicities with both of these agents, and when added together, patients need to be carefully monitored, concludes Hwang.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD